NCT03793634.

Trial name or title	Evaluation of topical chamomile vs topical triamcinolone acetonide in management of oral lichen planus
Methods	Parallel, double‐blind, RCT Egypt
Participants	Adults aged 30–80 years with OLP Inclusion criteria: symptomatic OLP; no history of taking corticosteroids for the last 6 months; people who agree to take medication; "medically free" Exclusion criteria: oral lesions other than OLP; lichenoid reaction; pregnancy or breastfeeding; smokers
Interventions	Group A: topical chamomile Group B: topical triamcinolone acetonide
Outcomes	Primary outcome: pain (numerical rating scale) Secondary outcome: clinical sign scores (Thongprasom)
Starting date	Not reported
Contact information	Esraa Nashat, Cairo University
Notes

CMC: carboxymethyl cellulose; ELISA: enzyme‐linked immunosorbent assay; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; IFNα: interferon‐α; OHIP: Oral Health Impact Profile; OLP: oral lichen planus; OLPClinROM: OLP Clinician Reported Outcome Measure; OLPSSM: Oral Lichen Planus Symptom Severity Measure; PUVA: psoralen and ultraviolet A; SF‐36: 36‐item Short Form; RCT: randomised controlled trial; TBA: thiobarbituric acid; UVB: ultraviolet B; VAS: visual analogue scale; WHO: World Health Organization.